Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,980 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Iranzo V, Sirera R, Carrato A, Cabrera A, Jantus E, Guijarro R, Sanmartín E, Blasco A, Gil M, Gómez-Aldaraví L, González-Larriba JL, Massuti B, Velasco A, Provencio M, Rossell R, Camps C. Iranzo V, et al. Among authors: gil m. Clin Transl Oncol. 2011 Jun;13(6):411-8. doi: 10.1007/s12094-011-0675-0. Clin Transl Oncol. 2011. PMID: 21680302 Clinical Trial.
Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.
Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA. Mayo-de-Las-Casas C, et al. Among authors: gil ml. Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288. Ann Oncol. 2017. PMID: 28911086 Free article.
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. García-Albéniz X, et al. Among authors: gil m. Oncologist. 2019 Nov;24(11):e1115-e1122. doi: 10.1634/theoncologist.2018-0728. Epub 2019 Jun 24. Oncologist. 2019. PMID: 31235483 Free PMC article. Clinical Trial.
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry.
Plazas JG, Arias-Martinez A, Lecumberri A, Martínez de Castro E, Custodio A, Cano JM, Hernandez R, Montes AF, Macias I, Pieras-Lopez A, Diez M, Visa L, Tocino RV, Lago NM, Limón ML, Gil M, Pimentel P, Mangas M, Granja M, Carnicero AM, Pérez CH, Gonzalez LG, Jimenez-Fonseca P, Carmona-Bayonas A. Plazas JG, et al. Among authors: gil m. ESMO Open. 2022 Jun;7(3):100514. doi: 10.1016/j.esmoop.2022.100514. Epub 2022 Jun 14. ESMO Open. 2022. PMID: 35714478 Free PMC article.
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
Arias-Martinez A, Martínez de Castro E, Gallego J, Arrazubi V, Custodio A, Fernández Montes A, Diez M, Hernandez R, Limón ML, Cano JM, Vidal-Tocino R, Macias I, Visa L, Martin Richard M, Sauri T, Hierro C, Gil M, Cerda P, Martínez Moreno E, Martínez Lago N, Mérida-García AJ, Gómez González L, García Navalón FJ, Ruiz Martín M, Marín G, López-López F, Ruperez Blanco AB, Fernández AF, Jimenez-Fonseca P, Carmona-Bayonas A, Alvarez-Manceñido F. Arias-Martinez A, et al. Among authors: gil m. Clin Transl Oncol. 2024 Jul;26(7):1674-1686. doi: 10.1007/s12094-024-03388-6. Epub 2024 Feb 15. Clin Transl Oncol. 2024. PMID: 38361134 Free PMC article.
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma.
Cabeza-Segura M, Gambardella V, Gimeno-Valiente F, Carbonell-Asins JA, Alarcón-Molero L, González-Vilanova A, Zuñiga-Trejos S, Rentero-Garrido P, Villagrasa R, Gil M, Durá A, Richart P, Alonso N, Huerta M, Roselló S, Roda D, Tarazona N, Martínez-Ciarpaglini C, Castillo J, Cervantes A, Fleitas T. Cabeza-Segura M, et al. Among authors: gil m. Br J Cancer. 2022 Dec;127(12):2198-2206. doi: 10.1038/s41416-022-02005-z. Epub 2022 Oct 17. Br J Cancer. 2022. PMID: 36253523 Free PMC article.
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
Valcarcel S, Gallego J, Jimenez-Fonseca P, Diez M, de Castro EM, Hernandez R, Arrazubi V, Custodio A, Cano JM, Montes AF, Macias I, Visa L, Calvo A, Tocino RV, Lago NM, Limón ML, Granja M, Gil M, Pimentel P, Macia-Rivas L, Pérez CH, Mangas M, Carnicero AM, Cerdà P, Gonzalez LG, Navalon FG, Rambla MDM, Richard MM, Carmona-Bayonas A. Valcarcel S, et al. Among authors: gil m. J Cancer Res Clin Oncol. 2023 Jul;149(7):4077-4089. doi: 10.1007/s00432-022-04294-6. Epub 2022 Aug 30. J Cancer Res Clin Oncol. 2023. PMID: 36042046
1,980 results